Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Tamiflu opvejede risiciene ved behandling og forebyggelse af influenza som supplerende metode under en pandemi, eller når influenzavaccinationerne ikke er effektive mod den influenzavirus, der forårsager den sæsonbetingede epidemi.
The Committee for Medicinal Products for Human Use (CHMP) decided that Tamiflu’ s benefits are greater than its risks for the treatment and prevention of influenza, as an additional method in case of a pandemic or when flu vaccines are not effective against the influenza virus causing the seasonal epidemic.